Akademik Veri Yönetim Sistemi
TBS International Biochemistry Congress 2024 - 35th National Biochemistry Congress, Antalya, Türkiye, 28 Ekim - 01 Kasım 2024, cilt.49, sa.1, ss.84-85, (Özet Bildiri)
Objectives: Glioblastoma multiforme (GBM) remains
one of the most aggressive malignant tumors in
the central nervous system with low survival rate. Insufficient
standard care of the disease provoked need
for an alternative treatment. Photodynamic therapy
(PDT) is a treatment modality which induces oxidative
stress, leading to cell death. Our main aim is to
determine the potential anticancer effect of a novel
silicon-rhodamine-based photosensitizer N-(2-bromo-
7-(dimethylamino)-5,5-dimethyl-10-(o-tolyl)dibenzo[
b,e]silin-3(5H)-ylidene)-N-methylmethanaminium
(2-Me-SiR-Br).
Methods: U87-MG glioblastoma cells were treated for
0.5-2 h followed by 4- and 6-min (650nm, 364.8mW/
cm2) light irradiation in fresh medium and overnight
incubation (24 h) to stimulate photodynamic effect.
On the other hand, to evaluate the dark toxicity, cells
were treated for 2 h followed by overnight incubation
in fresh medium (24 h) without light irradiation. MTT
assay was used to determine the cytotoxicity. Subcellular
localization in mitochondria and lysosome at 1
hour was performed with confocal microscopy.
Results: IC50 values of 2-Me-SiR-Br following 1-hour
treatment irradiated for 4-and 6-min with laser was
determined as 3.61±0.12 μM and 2.72±0.12 μM, respectively.
However, the IC50 value of the agent even
after 2-hour treatment was calculated as 15.17±0.48
μM, without light irradiation. Pearson correlation1-hour incubation is 0.95 and 0.92, respectively, which
indicates localization in both organelles.
Conclusions: Our findings demonstrate that 2-Me-
SiR-Br exhibits dramatic phototoxicity as opposed
to a weaker effect in the dark, indicating that 2-Me-
SiR-Br may be a powerful PDT agent to overcome
GBM, at least in vitro. This study is supported by ERC
852614 project grant.
Keywords: Glioblatoma Multiforme, PDT, Cancer,
Photosensitizer